• Iksuda Therapeutics will present initial Phase 1 results for IKS03 in advanced B-cell non-Hodgkin lymphoma at ASH on December 14, 2026.
• The treatment showed early antitumor activity in heavily pretreated patients, including those previously treated with CAR-T cell therapy.
• Side effects were generally manageable; no patients discontinued treatment because of adverse events.
• Dose escalation remains ongoing, with updated results due at the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IP Group plc published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.